Advertisement
Canada markets closed

  • S&P/TSX

    21,807.37
    +98.93 (+0.46%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CAD/USD

    0.7275
    +0.0012 (+0.16%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • Bitcoin CAD

    87,340.64
    +640.87 (+0.74%)
     

  • CMC Crypto 200

    1,372.44
    +59.81 (+4.55%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • RUSSELL 2000

    1,947.66
    +4.70 (+0.24%)
     

  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     

  • NASDAQ

    15,282.01
    -319.49 (-2.05%)
     

  • VOLATILITY

    18.71
    +0.71 (+3.94%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

Today’s Research Reports on Aurinia Pharmaceuticals, Knight Therapeutics, Aralez Pharmaceuticals and Microbix Biosystems

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / May 25, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

Aurinia Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=AUP.TO

Knight Therapeutics Inc.
https://rdinvesting.com/news/?ticker=GUD.TO

Aralez Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=ARZ.TO

Microbix Biosystems Inc.
https://rdinvesting.com/news/?ticker=MBX.TO

ADVERTISEMENT

Aurinia Pharmaceuticals' stock edged 0.53% higher Thursday, to close the day at $7.53. The stock recorded a trading volume of 13,400 shares, which was below its three months average volume of 40,839 shares. In the last year, Aurinia Pharmaceuticals' shares have traded in a range of 5.68 - 9.75. The share price has gained 32.57% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $7.03 is greater than its 200-day moving average of $6.78. Shares of Aurinia Pharmaceuticals have gained approximately 31.64 percent year-to-date.

Access RDI's Aurinia Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=AUP.TO

On Thursday, shares of Knight Therapeutics recorded a trading volume of 91,641 shares, which was below the three months average volume of 146,154 shares. The stock ended the day 0.12% lower at 8.14. The stock is currently trading 21.96% below its 52-week high with a 52-week trading range of 7.38 - 10.43. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $7.91 is greater than its 200-day moving average of $7.87. Shares of Knight Therapeutics Inc. are trading at a Price to Earnings ratio of 64.09. Shares of Knight Therapeutics have fallen approximately 2.05 percent year-to-date.

Access RDI's Knight Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=GUD.TO

Aralez Pharmaceuticals' stock moved 1.96% lower Thursday, to close the day at $0.50. The stock recorded a trading volume of 34,000 shares, which was below its three months average volume of 101,726 shares. In the last year, Aralez Pharmaceuticals' shares have traded in a range of 0.47 - 3.72. The stock is currently trading 86.56% below its 52 week high. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $1.42 is below its 200-day moving average of $1.93. Shares of Aralez Pharmaceuticals have fallen approximately 72.07 percent year-to-date.

Access RDI's Aralez Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ARZ.TO

On Thursday, shares of Microbix Biosystems recorded a trading volume of 43,700 shares, which was below the three months average volume of 47,501 shares. The stock ended the day flat at 0.285. The stock is currently trading 28.75% below its 52-week high with a 52-week trading range of 0.25 - 0.40. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.293 is below its 200-day moving average of $0.296. Shares of Microbix Biosystems have fallen approximately 8.06 percent year-to-date.

Access RDI's Microbix Biosystems Inc. Research Report at:
https://rdinvesting.com/news/?ticker=MBX.TO

Our Actionable Research on Aurinia Pharmaceuticals Inc. (TSX :AUP.TO), Knight Therapeutics Inc. (TSX :GUD.TO), Aralez Pharmaceuticals Inc. (TSX :ARZ.TO) and Microbix Biosystems Inc. (TSX :MBX.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com